F Salazar Molina*, J Lara Alcántara, MP Pinto, LA Piñon, MF Arabena Bilbao, JA Costa and P Servienti

Clinical Oncology Service, Hospital General de Agudos Dr. T. Álvarez, CABA, Argentina

*Corresponding Author: F Salazar Molina, Clinical Oncology Service, Hospital General de Agudos Dr. T. Álvarez, CABA, Argentina.

Received: August 06, 2024; Published: September 23, 2024

Abstract

Paragangliomas (PGL) are neuroendocrine tumors that occur in the ganglia of the autonomic nervous system. They share their embryonic origin with pheochromocytomas. They are differentiated from the latter by their low catecholamine secretory power, their extra-adrenal location, low malignant potential and lower incidence and prevalence. The heterogeneity with which they present makes their clinical presentation very varied and diagnosis a challenge. The indicated treatment will depend on the extent of the disease and relationship with adjacent structures, prioritizing surgical resection for its localized form as standard.

The clinical case of a patient with a diagnosis of carotid glomus paraganglioma is presented below, as a kickstart for the development of this topic of interest due to its low frequency of appearance.

Keywords: Paraganglioma; Pheochromocytoma; Pheochromocytoma/Paraganglioma Síndrome; Carotid Glomus

References

1. Garcia-Carbonero R., et al. “Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas”. Clinical and Translational Oncology 10 (2021): 1995-2019.
2. Young WF. “Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology”. UpToDate (2023).
3. Lee JA and Duh QY. “Sporadic paraganglioma”. World Journal of Surgery 5 (2008): 683-687.
4. El-Ashry A., et al. “Cardiac Paraganglioma”. Journal of Cardiac Surgery 2 (2014): 135-139.
5. Sandow L., et al. “Paraganglioma of the Head and Neck: A Review”. Endocrine Practice 2 (2023): 141-147.
6. Taïeb D., et al. “Current approaches and recent developments in the management of head and neck paragangliomas”. Endocrine Reviews 35 (2014): 795-819.
7. Lee JH., et al. “National cancer data base report on malignant paragangliomas of the head and neck”. Cáncer 94 (2002): 730-737.
8. Leung AA., et al. “Epidemiology of pheochromocytoma and paraganglioma: population-based cohort study”. European Journal of Endocrinology 1 (2021): 19-28.
9. Joynt KE., et al. “Paragangliomas. Etiology, Presentation, and Management”. Cardiology in Review (2017): 4.
10. Rodríguez-Cuevas S., et al. “Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level”. Head Neck5 (1998): 374-378.
11. Astrom K., et al. “Altitude is a phenotypic modifier in hereditary paraganglioma type 1: Evidence for an oxygen-sensing defect”. Human Genetics 3 (2003): 228-237.
12. Gonzalez-Orus Alvarez-Morujo RJ., et al. “Head and neck paragangliomas: Experience in 126 patients with 162 tumours”. Acta Otorrinolaringologica (English Edition) 66 (2015): 332-341.
13. Arora S., et al. “Prospective evaluation of 68Ga-DOTANOC positron emission tomography/computed tomography and 131I-meta-iodobenzylguanidine single-photon emission computed tomography/computed tomography in extra-adrenal paragangliomas, including uncommon primary sites and to define their diagnostic roles in current scenario”. Nuclear Medicine Communications 12 (2019): 1230-1242.
14. Bozkurt MF., et al. “Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA”. European Journal of Nuclear Medicine and Molecular Imaging 9 (2017): 1588-1601.
15. Williams MD. “Paragangliomas of the head and neck: an overview from diagnosis to genetics”. Head and Neck Pathology 3 (2017): 278-287.
16. Gimm O., et al. “Malignant pheochromocytomas and paragangliomas: a diagnostic challenge”. Langenbeck's Archives of Surgery 2 (2017): 155-177.
17. Kliewer KE and Cochran AJ. “A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas”. Archives of Pathology and Laboratory Medicine11 (1989): 1209-1218.
18. Shamblin WR., et al. “Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases”. American Journal of Surgery6 (1971): 732-739.
19. Neumann HP., et al. “Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations”. JAMA 8 (2004): 943-951.
20. Schiavi F., et al. “Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene”. JAMA16 (2005): 2057-2063.
21. Baysal BE., et al. “Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma”. Science (New York, N.Y.)5454 (2000): 848-851.
22. Petr EJ and Else T. “Genetic predisposition to endocrine tumors: Diagnosis, surveillance and challenges in care”. Seminars in Oncology5 (2016): 582-590.
23. Sajid MS., et al. “A multicenter review of carotid body tumor management”. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery2 (2007): 127-130.
24. Hinerman RW., et al. “Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience”. Head and Neck11 (2008): 1431-1438.
25. Noto RB., et al. “Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma”. The Journal of Clinical Endocrinology and Metabolism1 (2018): 213-220.
26. Averbuch SD., et al. “Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine”. Annals of Internal Medicine4 (1988): 267-273.
27. Ayala-Ramirez M., et al. “Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience”. Cancer11 (2012): 2804-2812.

Citation

Citation: J Lara Alcántara., et al. “Paraganglioma of the Carotideal Glomus Bibliographic Review of a Rare Tumor about a Case”.Acta Scientific Medical Sciences 8.10 (2024): 102-106.

Copyright

Copyright: © 2024 J Lara Alcántara., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.